(Q40997864)

25 September 2017

title

Postconfluent multilayered cell line cultures for selective screening of gemcitabine (English)

1 reference

25 September 2017

E Smitskamp-Wilms

1

1 reference

25 September 2017

H M Pinedo

2

1 reference

25 September 2017

G Veerman

3

1 reference

25 September 2017

V W Ruiz van Haperen

4

1 reference

25 September 2017

G J Peters

5

1 reference

25 September 2017

publication date

1 May 1998

1 reference

European Journal of Cancer

25 September 2017

published in

1 reference

25 September 2017

volume

34

1 reference

25 September 2017

issue

6

1 reference

25 September 2017

page(s)

921-926

1 reference

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Gemcitabine: current status of phase I and II trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

New colorimetric cytotoxicity assay for anticancer-drug screening

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Preclinical characteristics of gemcitabine.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910125-3

7 January 2021

10.1016/S0959-8049(97)10125-3

Identifiers

DOI

1 reference

25 September 2017

1 reference